CDN Maverick Capital Corp. (CSE:CDN) Clarifies NCIB and Announces Stock Option Grant

Vancouver, British Columbia — January 20, 2026 — Leads & Copy — CDN Maverick Capital Corp. has clarified that its normal course issuer bid (NCIB) purchases will begin on Wednesday, Jan. 21, 2026, in accordance with Canadian Securities Exchange policies.

The company initially announced the NCIB in a news release dated Jan. 16, 2026. All other terms of the NCIB remain unchanged.

In addition, the company’s board of directors has approved granting stock options to certain directors under its existing equity incentive plan. A total of 600,000 stock options have been granted, each allowing the holder to acquire one common share of the company at CAD $0.295 per share.

The options have a five-year term from the grant date and are exercisable per the company’s equity incentive plan and securities legislation. The options vest immediately, contingent on the participant’s continued service with the company.

According to Simon D. Studer, Interim President and CEO of CDN Maverick Capital Corp., the options recognize the board members’ commitment and strategic guidance as the company advances its portfolio of critical mineral and exploration projects.

Securities issued under the stock option grant are subject to a four-month hold period from the grant date, following securities laws and Canadian Securities Exchange policies.

CDN Maverick Capital Corp. is a project generator and critical minerals exploration company focused on identifying and developing high-value assets using data-driven exploration strategies. The company is advancing a portfolio of lithium and battery metals projects across tier-one mining jurisdictions in North America.

Sandy MacDougall, Founder, Chairman, and Director, can be reached at sandyjmacdougall@gmail.com or +1 778 999 2159. Simon Studer, Interim CEO and Director, can be reached at simondavidstuder@gmail.com or 0041 44 585 24 84.

Source: CDN Maverick Capital Corp.

×

Welcome!

Biotech Reporter is the source most up-to-date real-time, direct-from-source News Tips and Story Leads.

By Subscribing you will receive Daily Biotech Update each day at 9:30 am ET (Market Open) in your inbox and you can unsubscribe any time.